Atossa Therapeutics plans stapled CVR issuance tied to potential FDA priority review voucher proceeds
ATOS•Atossa plans to attach one non-separately tradable contingent value right to each ATOS share, with holders eligible for 25% of net proceeds from monetizing its first qualifying FDA priority review voucher, capped at $50 million in aggregate; no voucher has been awarded.
1. CVR plan
Atossa outlined a plan to staple one contingent value right to each common share, tied to monetizing its first qualifying FDA priority review voucher. The CVRs would transfer with the shares, would not trade separately or be registered, and would not have their own CUSIP. Holders would receive 25% of net monetization proceeds, capped at $50 million in aggregate, if a qualifying voucher is obtained. No voucher has been awarded, and the CVRs would expire on Dec. 31, 2036, unless extended.
